OBJECTIVE: To estimate the incremental cost of implementing policies for intensive control of blood glucose concentration and blood pressure for all patients with type 2 diabetes in England. DESIGN: Extrapolation of resource use and cost data derived from a randomised controlled trial. SETTING: General practice, outpatient care, and inpatient care. POPULATION: Trial population with diagnosed type 2 diabetes in England extrapolated to the population of England. MAIN OUTCOME MEASURES: Total costs based on use of healthcare resources including costs of management, treatment, and hospitalisation. RESULTS: The incremental net annual cost of implementing intensive control of blood glucose and blood pressure to all people with diagnosed type 2 dia...
Aims/hypothesis. to estimate the economic efficiency of intensive blood-glucose control with metform...
Type 2 diabetes (T2DM) results in a heavy burden on healthcare resources, and this burden is increas...
Background: Two alternative basal analogue insulin treatments are available: insulin glargine (glarg...
OBJECTIVE: To estimate the cost effectiveness of conventional versus intensive blood glucose control...
AIMS/HYPOTHESIS: This study estimated the economic efficiency (1) of intensive blood glucose control...
Objectives: To estimate the economic efficiency of tight blood pressure control, with angiotensin co...
The UKPDS group has concluded that cost of intensive blood glucose control in type 2 diabetes is lar...
Aims The purpose of this study was to characterize the financial cost and efficacy of primary care t...
Objectives: To estimate the economic efficiency of tight blood pressure control, with angiotensin co...
AIMS: To examine the short- and long-term cost-effectiveness of intensive multifactorial treatment c...
Aims To examine the short- and long-term cost-effectiveness of intensive multifactorial treatment co...
BACKGROUND: There is uncertainty about the cost effectiveness of early intensive treatment versus ro...
Aims Diabetes represents a notable burden to health payers. The purpose of this study was to estimat...
Aims: Medication therapy for type 2 diabetes has become increasingly complex, and there is little re...
This is the author accepted manuscript. The final version is available from Springer Verlag via the ...
Aims/hypothesis. to estimate the economic efficiency of intensive blood-glucose control with metform...
Type 2 diabetes (T2DM) results in a heavy burden on healthcare resources, and this burden is increas...
Background: Two alternative basal analogue insulin treatments are available: insulin glargine (glarg...
OBJECTIVE: To estimate the cost effectiveness of conventional versus intensive blood glucose control...
AIMS/HYPOTHESIS: This study estimated the economic efficiency (1) of intensive blood glucose control...
Objectives: To estimate the economic efficiency of tight blood pressure control, with angiotensin co...
The UKPDS group has concluded that cost of intensive blood glucose control in type 2 diabetes is lar...
Aims The purpose of this study was to characterize the financial cost and efficacy of primary care t...
Objectives: To estimate the economic efficiency of tight blood pressure control, with angiotensin co...
AIMS: To examine the short- and long-term cost-effectiveness of intensive multifactorial treatment c...
Aims To examine the short- and long-term cost-effectiveness of intensive multifactorial treatment co...
BACKGROUND: There is uncertainty about the cost effectiveness of early intensive treatment versus ro...
Aims Diabetes represents a notable burden to health payers. The purpose of this study was to estimat...
Aims: Medication therapy for type 2 diabetes has become increasingly complex, and there is little re...
This is the author accepted manuscript. The final version is available from Springer Verlag via the ...
Aims/hypothesis. to estimate the economic efficiency of intensive blood-glucose control with metform...
Type 2 diabetes (T2DM) results in a heavy burden on healthcare resources, and this burden is increas...
Background: Two alternative basal analogue insulin treatments are available: insulin glargine (glarg...